Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

V-125 is an agonist of retinoid X receptors (RXRs).1 It induces homodimerization of RXR in HCT116 cells in a two-hybrid assay (EC50 = 13.8 nM). V-125 selectively induces transactivation of RXRα in human RXRα-overexpressing HCT116 cells over transactivation of RARα in human RARα-overexpressing HEK293 cells when used at concentrations of 25 and 100 nM, respectively. In vivo, V-125 (80 mg/kg in the diet) inhibits vinyl carbamate-induced lung tumor growth in mice.2 Unlike the RXR agonist bexarotene (Item No. 11571), V-125 does not increase plasma triglyceride or cholesterol levels in mice.
WARNING This product is not for human or veterinary use.
1. Modeling, synthesis, and biological evaluation of potential retinoid X receptor (RXR)-
2. The rexinoid V‑125 reduces tumor growth in preclinical models of breast and lung cancer. Sci. Rep. 12(1), 293 (2022).